FDA Clearance Tracker · P240042-S002
Tendyne Transcatheter Mitral Valve System
Last checked: Nov 20, 2026Latest source record: Oct 4, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Oct 4, 2025
Approved
Time to decision
30 days
Received Sep 4, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P240042-S002
- Device name
- Tendyne Transcatheter Mitral Valve System
- Applicant
- ABBOTT MEDICAL
- Applicant location
- St. Paul, MN
- Received
- Sep 4, 2025
- Decided
- Oct 4, 2025
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P240042
Device type
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval of the protocol for the post-approval study, "Registry-Based Real-World Use Surveillance," submitted to comply with the conditions of approval outlined in the approval order for P240042.
Source documents
Other decisions for ABBOTT MEDICAL
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P260019 · Decided Oct 27, 2026 · 180 days after receipt
Device type: Para-device leak occluder (SJT) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.